NO976112L - 1,6-disubstituerte isokromaner for behandling av migrene - Google Patents

1,6-disubstituerte isokromaner for behandling av migrene

Info

Publication number
NO976112L
NO976112L NO976112A NO976112A NO976112L NO 976112 L NO976112 L NO 976112L NO 976112 A NO976112 A NO 976112A NO 976112 A NO976112 A NO 976112A NO 976112 L NO976112 L NO 976112L
Authority
NO
Norway
Prior art keywords
treatment
isochromes
disubstituted
migraine
useful
Prior art date
Application number
NO976112A
Other languages
English (en)
Other versions
NO976112D0 (no
Inventor
Michael D Ennis
Ruth E Tenbrink
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of NO976112D0 publication Critical patent/NO976112D0/no
Publication of NO976112L publication Critical patent/NO976112L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Foreliggende oppfinnelse angår 1,6-disubstituerte isokromaner av formel (I) og aromatiske, bisykliske aminer (ABA) som er anvendbare for behandling av hodepine, spesielt migrene og klase- hodepine, og også anvendbare som anti- psykotiske midler og for behandling av andre CNS og/eller kardiovaskulære syk- dommer, og som analgetiske midler.
NO976112A 1995-06-30 1997-12-29 1,6-disubstituerte isokromaner for behandling av migrene NO976112L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74195P 1995-06-30 1995-06-30
US1123496P 1996-02-06 1996-02-06
PCT/US1996/008681 WO1997002259A1 (en) 1995-06-30 1996-06-07 1,6-disubstituted isochromans for treatment of migraine headaches

Publications (2)

Publication Number Publication Date
NO976112D0 NO976112D0 (no) 1997-12-29
NO976112L true NO976112L (no) 1998-03-02

Family

ID=26668092

Family Applications (1)

Application Number Title Priority Date Filing Date
NO976112A NO976112L (no) 1995-06-30 1997-12-29 1,6-disubstituerte isokromaner for behandling av migrene

Country Status (12)

Country Link
EP (1) EP0836599A1 (no)
JP (1) JPH11509532A (no)
AU (1) AU6252296A (no)
BR (1) BR9609631A (no)
CA (1) CA2225282A1 (no)
CZ (1) CZ418597A3 (no)
FI (1) FI974640A (no)
MX (1) MX9710260A (no)
NO (1) NO976112L (no)
PL (1) PL324319A1 (no)
SK (1) SK164297A3 (no)
WO (1) WO1997002259A1 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2370270A (en) * 2000-12-20 2002-06-26 Lilly Co Eli Pharmaceutical compounds
US7335660B2 (en) 2001-12-19 2008-02-26 Eli Lilly And Company Isochroman compounds for treatment of CNS disorders
GB0130339D0 (en) * 2001-12-19 2002-02-06 Lilly Co Eli Isochroman compounds
US7110576B2 (en) 2002-12-30 2006-09-19 Pitney Bowes Inc. System and method for authenticating a mailpiece sender
RU2372344C2 (ru) 2004-05-05 2009-11-10 Ф. Хоффманн-Ля Рош Аг Арилсульфонилбензодиоксаны, применяемые для модуляции 5-нт6 рецептора, 5-нт2a рецептора или и того, и другого
CN101119965B (zh) 2004-12-21 2012-09-26 弗·哈夫曼-拉罗切有限公司 萘满和茚满衍生物及其用途
BRPI0515830A (pt) 2004-12-21 2008-08-05 F Hoffmann La Roche derivados de cromano e usos dos mesmos no tratamento de distúrbios do sistema nervoso central
ES2306275T3 (es) 2004-12-21 2008-11-01 F. Hoffmann-La Roche Ag Derivados de cromano y sus usos como ligandos dde receptores 5-ht.
AU2005318598B2 (en) 2004-12-21 2010-08-26 F. Hoffmann-La Roche Ag Tetralin and indane derivatives and uses thereof as 5-HT antagonists
CA2591793A1 (en) 2004-12-21 2006-06-29 F. Hoffmann-La Roche Ag Tetralin and indane derivatives and uses thereof
DE602006020351D1 (en) 2005-11-03 2011-04-07 Hoffmann La Roche Arylsulfonylchromane als 5-ht6-inhibitoren
JP2009541249A (ja) 2006-06-20 2009-11-26 エフ．ホフマン−ラ ロシュ アーゲー アリールスルホニルナフタレン誘導体およびその使用
AU2007263084A1 (en) 2006-06-20 2007-12-27 F. Hoffmann-La Roche Ag Tetralin and indane derivatives and uses thereof
CA2655524A1 (en) 2006-06-20 2007-12-27 F. Hoffman-La Roche Ag Arylsulfonamidyl tetralin derivatives and uses thereof
EP2404897A4 (en) * 2009-03-05 2014-02-26 Sumitomo Chemical Co PROCESS FOR PREPARING HALOGEN-SUBSTITUTED BENCHENETIMETHANOL

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1552004A (en) * 1976-05-26 1979-09-05 Takeda Chemical Industries Ltd Isochroman derivatives
EP0737189B1 (en) * 1993-12-28 1999-07-28 PHARMACIA & UPJOHN COMPANY Heterocyclic compounds for the treatment of cns and cardiovascular disorders

Also Published As

Publication number Publication date
WO1997002259A1 (en) 1997-01-23
SK164297A3 (en) 1998-09-09
AU6252296A (en) 1997-02-05
CZ418597A3 (cs) 1998-06-17
PL324319A1 (en) 1998-05-25
CA2225282A1 (en) 1997-01-23
JPH11509532A (ja) 1999-08-24
FI974640A0 (fi) 1997-12-30
MX9710260A (es) 1998-03-29
FI974640A (fi) 1997-12-30
NO976112D0 (no) 1997-12-29
BR9609631A (pt) 1999-03-02
EP0836599A1 (en) 1998-04-22

Similar Documents

Publication Publication Date Title
NO976112L (no) 1,6-disubstituerte isokromaner for behandling av migrene
YU64092A (sh) Fluoralkoksibenzamino derivati heterocikličnih jedinjenja koja sadrže azot
FI941022A (fi) Spirosykliset piperidiinijohdannaiset
FI931370A0 (fi) Kvaeve innehaollande analoger av icke-aromatiska heterocykliska foereningar med en fusionerad ring
NO955047L (no) Sekundære aminer som antidiabetiske og antifedme-midler
MX9702865A (es) Agentes estrogenicos.
ATE263157T1 (de) Nematizide trifluorbutene
MD1838G2 (ro) Derivaţi de 5,6-diclorbenzimidazol, procedeu de obţinere a lor, compoziţie farmaceutică şi metodă de tratament sau de prevenire a infecţiei virotice herpetice
DK0772604T3 (da) Trialzolforbindelser og deres anvendelse som dopamin-D3-ligander
NO20006645L (no) Ny form av irbesartan, fremgangsmåte for å oppnå den nevnte form og farmasöytiske preparater inneholdende den samme
DK0934309T3 (da) Nye pyridylalkansyreamider som cytostatiske og immunosuppressive midler
DK0737189T3 (da) Heterocycliske forbindelser til behandling af CNS-forstyrrelser og cardiovaskulære forstyrrelser
DE69530988T2 (de) Benzimidazolderivate mit dopaminerger wirkung
IS6914A (is) 2-þíó-útskiptar imídasólafleiður og notkun þeirraí lyfjaiðnaðinum
BR0113461A (pt) Compostos ou sais farmaceuticamente aceitáveis, composições farmacêuticas, método de tratamento de doença ou condição mediada por erab, hadh2 ou (beta)-amilóide em mamìferos, métodos de inibição ou modulação da atividade enzimática de erab ou hadh2 e método de tratamento de mal de alzheimer ou demência em mamìferos
NO970573D0 (no) Ylidenforbindelser og deres fremstilling
YU22802A (sh) Izonipekotamidi za lečenje poremećaja nastalih posredstvom integrina
HUP0001118A2 (hu) N-szubsztituált pirrolidinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
DE59406501D1 (de) Substituierte iminoacetonitrile mit myokardprotektiver wirkung
NO970498L (no) Benzimidazolderivater med dopaminergisk aktivitet
MX9704733A (es) Monomeros de ciclohesan-1-ona 4,4-disubstituidos y compuestos relacionados.